Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid ...

The stock's fall snapped a four-day winning streak.

Eli Lilly is set to launch Mounjaro in KwikPen, a user-friendly, prefilled pen for weekly administration, in India, following ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro, its widely used diabetes and weight-loss ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...